Platelet-Rich Plasma Growth Factor Concentrated Spray (Keratogrow®) as a Potential Treatment for Androgenic Alopecia.

The objective is to investigate the safety and clinical efficacy of Autologous Platelet Rich Plasma Concentrated Spray (Keratogrow®), for hair loss. Autologous -PRP spray, prepared from a small volume of blood, was applied on the selected patients' scalps at least twice daily. Three months treatments were given for each patient. The effectiveness of the medication was measured by changes in hair regrowth after 3 months determined by physical exam and digital photography. At the end of the 3 cycles of treatment, the patients presented clinical improvement in the mean number of hairs, with a mean increase of hairs in the target area, and a mean increase in total hair density compared with baseline values.

Efficacy of Activated 3X Platelet-Rich Plasma in the Treatment of Androgenic Alopecia.

BACKGROUND: Platelet-rich plasma (PRP) has shown remarkable beneficial effects without any major adverse reactions in the treatment of androgenic alopecia .The growth factors in activated autologous PRP induces the proliferation of dermal papilla cells. OBJECTIVES: To investigate the clinical efficacy of Platelet Rich Plasma prepared using Merisis One Step Gel Separation Technology in treatment of androgenic alopecia. METHODS: Five patients were given autologous PRP injections on the affected area of alopecia over a period of three months at interval of two - three weeks and results were assessed. RESULTS: Three months after the treatment, the patients presented clinical improvement in the hair counts, hair thickness, hair root strength and overall alopecia. CONCLUSION: PRP appears to be a cheap, effective and promising therapy for androgenic alopecia with no major adverse effects.

Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.

Azurin derived from P. aeruginosa MTCC 2453 were reported to be an important modulator in cancer regression which leads it to develop as a therapeutic drugs. Earlier studies reported that azurin derived from P. aeruginosa and other organisms, showed in vitro and in vivo antitumor properties by the induction of apoptosis. The present study was premeditated to evaluate the in vivo therapeutic efficacy of azurin from P. aeruginosa MTCC 2453 in Dalton's lymphoma (DL) mice model. The acute toxicity assay of azurin showed the 200 µg/kg as sublethal doses in normal mice. The acute toxicity like body weight, peripheral blood cell count, lympho-hematological and biochemical parameters remained unaffected till 200 µg/kg body weight of azurin. The growth inhibitory properties of azurin against in vivo DL model were vastly significant with its sublethal doses. We found that the DL cells survival rate percentage was 29.69, 64.6 and 88.79% in 50, 100 and 200 µg/kg body weight of azurin, respectively. Investigations of the growth inhibitory mechanism in DL cells were exposed by nuclear fragmentation, and the increased accumulation of DL cells in the sub-G0/G1 phases in cell cycle analysis are indications of apoptosis. Further, the cause of apoptosis was revealed by Western blot which showed the reduction in the ratio of Bcl-2 and Bax protein expression, the activation of caspases-3 through the release of cytochrome c in DL cells. The survival rate of tumor bearing DL mice treated with azurin analyzed by Kaplan Meir method showed an effective antitumor response as with a dose of 200 µg/kg body weight (an 94.19% increase in life span [ILS] %).